Summary
FLT Chart
Volatus Releases Fourth Quarter and Fiscal Year 2024 Financial Results
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.
Volatus Announces $2,000,000 Financing
Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annua
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including menin and FLT3 inhibitors and the hypomethylating agent (HMA) azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations.
FleetCor Technologies Inc (FLT) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has FleetCor Technologies Inc ever had a stock split?
FleetCor Technologies Inc Profile
| Software—Infrastructure Industry | Technology Sector | Mr. Ronald F. Clarke CEO | NYSE Exchange | US3390411052 ISIN |
| United States Country | 10,500 Employees | - Last Dividend | - Last Split | 15 Dec 2010 IPO Date |
Overview
FLEETCOR Technologies, Inc. is a prominent payments company that facilitates a wide range of expense management solutions for businesses and consumers, particularly those related to vehicle, lodging, and corporate payments. Having a global footprint, the company operates not only in the United States but also has a significant presence in Brazil, the United Kingdom, and other international markets. The company's operations are segmented into Vehicle Payments, Corporate Payments, Lodging Payments, and Others, demonstrating a diversified portfolio of payment solutions. Founded in 1986 and headquartered in Atlanta, Georgia, FLEETCOR has grown to become a key player in the payment solutions sector, serving a wide array of customers including businesses, merchants, consumers, and payment networks.
Products and Services
FLEETCOR Technologies, Inc. offers a comprehensive array of products and services tailored to meet the specific needs of their clients, ranging from vehicle payment solutions to corporate payment systems and beyond:
- Vehicle Payment Solutions: These include a variety of services to manage expenses related to fuel, tolls, parking, fleet maintenance, and long-haul transportation. These solutions are designed to streamline the management of vehicle-related expenses for businesses.
- Prepaid Food and Transportation Vouchers and Cards: FLEETCOR offers prepaid solutions to cover food and transportation expenses, providing an efficient way for businesses to manage these costs for their employees or customers.
- Corporate Payment Solutions: This range includes a suite of products aimed at simplifying the corporate payments process, such as accounts payable automation, virtual cards, cross-border payments solutions, and purchasing as well as travel and entertainment card products. These solutions are crafted to enhance operational efficiencies in corporate financial transactions.
- Lodging Payments Solutions: Tailored for employees traveling overnight for work, traveling crews, and stranded passengers from airlines and cruise lines, as well as insurance policyholders displaced from their homes due to damage or catastrophe, these solutions facilitate the simplification of managing lodging expenses under various circumstances.
- Gifts and Payroll Cards: FLEETCOR also provides gift and payroll card products, offering an alternative and possibly more convenient method for businesses to distribute rewards or payroll to their employees.
Contact Information
